Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies (Q38969861)

8 September 2017

title

Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies (English)

1 reference

8 September 2017

0 references

J J Shatzel

1

1 reference

8 September 2017

S R Olson

2

1 reference

8 September 2017

D L Tao

3

1 reference

8 September 2017

O J T McCarty

4

1 reference

8 September 2017

A V Danilov

5

1 reference

8 September 2017

T G DeLoughery

6

1 reference

8 September 2017

publication date

9 February 2017

1 reference

Journal of Thrombosis and Haemostasis

8 September 2017

published in

1 reference

8 September 2017

volume

15

1 reference

8 September 2017

issue

5

1 reference

8 September 2017

page(s)

835-847

1 reference

Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies

8 September 2017

cites work

1 reference

The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.

21 January 2018

1 reference

Primary immunodeficiency diseases due to defects in lymphocytes

21 January 2018

1 reference

Primary B cell immunodeficiencies: comparisons and contrasts

21 January 2018

1 reference

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

21 January 2018

1 reference

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

21 January 2018

1 reference

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

21 January 2018

1 reference

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

21 January 2018

1 reference

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

21 January 2018

1 reference

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

21 January 2018

1 reference

Ibrutinib in previously treated Waldenström's macroglobulinemia.

21 January 2018

1 reference

A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.

21 January 2018

1 reference

Tec regulates platelet activation by GPVI in the absence of Btk.

21 January 2018

1 reference

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.

21 January 2018

1 reference

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.

21 January 2018

1 reference

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

21 January 2018

1 reference

Platelet glycoprotein VI-related clinical defects

21 January 2018

1 reference

Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets

21 January 2018

1 reference

C-type lectin like receptor 2 (CLEC-2) signals independently of lipid raft microdomains in platelets

21 January 2018

1 reference

GPVI and CLEC-2 in hemostasis and vascular integrity

21 January 2018

1 reference

Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2

21 January 2018

1 reference

Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo

21 January 2018

1 reference

The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells.

21 January 2018

1 reference

Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.

21 January 2018

1 reference

A role for PKCtheta in outside-in alpha(IIb)beta3 signaling.

21 January 2018

1 reference

Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.

21 January 2018

1 reference

The evolution of antiplatelet therapy in cardiovascular disease

21 January 2018

1 reference

A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo

21 January 2018

1 reference

Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model

21 January 2018

1 reference

Impact of glycoprotein VI and platelet adhesion on atherosclerosis--a possible role of fibronectin.

21 January 2018

1 reference

The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE-/- mice

21 January 2018

1 reference

The future of glycoprotein VI as an antithrombotic target.

21 January 2018

1 reference

The VWF-GPIb axis in ischaemic stroke: lessons from animal models.

21 January 2018

1 reference

Targeting platelet GPIbβ reduces platelet adhesion, GPIb signaling and thrombin generation and prevents arterial thrombosis.

21 January 2018

1 reference

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

21 January 2018

1 reference

Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients

21 January 2018

1 reference

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

21 January 2018

1 reference

The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis

21 January 2018

1 reference

Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report

21 January 2018

1 reference

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling

21 January 2018

1 reference

Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment

21 January 2018

1 reference

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support

21 January 2018

1 reference

Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

21 January 2018

1 reference

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

21 January 2018

1 reference

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

21 January 2018

1 reference

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

21 January 2018

1 reference

Aspirin as an antiplatelet drug

21 January 2018

1 reference

Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients

21 January 2018

1 reference

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

21 January 2018

1 reference

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

21 January 2018

1 reference

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

21 January 2018

1 reference

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6152914

Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6152914

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6152914

The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports.

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6152914

Development of antibodies that interfere with the collagen-VWF-GPIb axis as new antithrombotics

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6152914

Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females

4 November 2018

1 reference

12 December 2020

Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury

1 reference

12 December 2020

Apixaban for extended treatment of venous thromboembolism

1 reference

12 December 2020

Genetic and antibody-induced glycoprotein VI deficiency equally protects mice from mechanically and FeCl(3) -induced thrombosis

1 reference

12 December 2020

Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial

1 reference

12 December 2020

Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury

1 reference

12 December 2020

A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques

1 reference

12 December 2020

Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions

1 reference

12 December 2020

The physiological and pathophysiological roles of platelet CLEC-2

1 reference

12 December 2020

Identifiers

DOI

10.1111/JTH.13651

1 reference

8 September 2017

0 references

1 reference